Patent highlight: brain-penetrant GCS inhibitors built on a triazolopyrimidine core
- This is a commentary on patent disclosures, not a report of primary experimental data; it describes claims made in a recent patent.
- The patent discloses triazolopyrimidine-derived analogs as inhibitors of glucosylceramide synthase (GCS) and claims them for conditions linked to GCS activity.
- Selected compounds are described as highly potent in GCS inhibition assays.
- Optimized analogs are reported to show brain penetration, microsomal stability and favorable plasma protein binding.
💡 Points
Triazolopyrimidine looks like a fairly unusual GCS chemotype next to the ceramide-mimetic and amine-heavy designs I'm used to, so scaffold novelty may be real, and a flat aromatic core is easy to decorate. But "highly potent" with no numbers, and nothing on selectivity, means I can't rank it against eliglustat-type or venglustat-type brain-penetrant compounds. These are patent claims, not peer-reviewed data.
Novel Triazolopyrimidine Analogs as Glucosylceramide Synthase Inhibitors ↗